Evidence map›Paper›PMID 30400422›Full record

ArticleMicromachines2017

A Droplet Microfluidics Based Platform for Mining Metagenomic Libraries for Natural Compounds.

Elias Theodorou, Randall Scanga, Mariusz Twardowski, Michael P Snyder, Eric Brouzes

Open access · goldAbstract read
In one paragraph

Article in Micromachines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Recent trends in biocatalysis.Chemical Society reviews · 2021
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Elias TheodorouMetagenomix Inc., Branford, CT 06405, USA. elias.theodorou1@gmail.com.
Randall ScangaDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. randallscanga@yahoo.com.
Mariusz TwardowskiDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. mariusz.t@gmail.com.
Michael P SnyderMetagenomix Inc., Branford, CT 06405, USA. mariusz.t@gmail.com.
Eric BrouzesMetagenomix Inc., Branford, CT 06405, USA. eric.brouzes@stonybrook.edu.ORCID 0000-0002-8102-0729
Massachusetts Institute of Technology · USStanford University · USStony Brook University · USYale University · US

Funding

High Throughput Metagenomic Drug Screening in Mammalian CellsR43GM095227 · NIGMS · METAGENOMIX, INC. · PI THEODOROU, ELIAS · 2010 to 2010
$100k
NIGMS NIH HHS R43 GM095227NIH HHS 1R43GM95227
6 · The paper itself

Abstract

Historically, microbes from the environment have been a reliable source for novel bio-active compounds. Cloning and expression of metagenomic DNA in heterologous strains of bacteria has broadened the range of potential compounds accessible. However, such metagenomic libraries have been under-exploited for applications in mammalian cells because of a lack of integrated methods. We present an innovative platform to systematically mine natural resources for pro-apoptotic compounds that relies on the combination of bacterial delivery and droplet microfluidics. Using the violacein operon from

Indexed as

droplet microfluidicshigh-throughput screeningmetagenomic screeningnatural compound

Identifiers

PMID30400422
PMCPMC6189830
OpenAlexW2736807460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.